Debbie Rigby presents the latest research relevant to pharmacists from around the world
Patient-reported outcomes on the use of all-oral direct acting antivirals for the treatment of chronic hepatitis C show better patient experience and work productivity during treatment. Data from multicenter multinational phase 3 clinical trials of sofosbuvir with and without interferon or ribavirin showed a sustained virological response 12 weeks post-treatment (SVR12) regardless of regimen.
The American Journal of Gastroenterology, 29 March 2016.
This review of 173,321 patients on PPIs and 20,270 on H2 antagonists, with follow-up over 5 years, found that PPIs had a significantly elevated risk of doubling of serum creatinine level, an increased risk of incident eGFR decline > 30% and end stage renal disease compared to H2-blockers.
Journal of the American Society of Nephrology. Published online April 14, 2016.
This article provides a rationale as to why specific diets might improve IBS symptoms. Elimination of one food (ie, lactose, fructose, excess fiber, fructans, and galactans) at a time may improve GI symptoms. A low FODMAP diet may help patients who have failed individual dietary interventions.
Clin Gastroenterol Hepatol. 2015;13(11):1899-1906.
Canagliflozin, a SGLT2 inhibitor for the treatment of type 2 diabetes, improves glycaemic control, body weight, and BP in people aged 75 and older. Randomized Phase 3 studies have shown the overall incidence of adverse events is high across treatment groups in participants aged 75 and older and higher than in those younger than 75.
J Am Geriatr Soc. 2016;64(3):543-552.